title: Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.
abstract: Immune-driven inflammation plays an important part in atherogenesis and is therefore believed to be key to the development of cardiovascular disease (CVD), which is currently the leading cause of death in the Western world. By fulfilling some of the Koch postulates, atherogenesis has even been proposed to be considered as an autoimmune disease, raising the hope that CVD could be prevented by immunomodulation. Nevertheless, the role of the immune system and autoimmune reactions in atherosclerosis appear to be a double edged-sword, with both pro-atherogenic and anti-atherogenic attributes. Hence, if immunomodulation is to become a therapeutic option for atherosclerosis and CVD, it will be crucial to correctly identify patients who might benefit from targeted suppression of deleterious autoimmune responses. This could be achieved, for example, by the detection of disease-associated autoantibodies. In this work, we will review the currently available clinical, in vitro, and animal studies dedicated to autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG), the major proteic fraction of high density lipoprotein. Current clinical studies indicate that high levels of anti-apoA-1 IgG are associated with a worse cardiovascular prognosis. In addition, in vitro and animal studies indicate a pro-inflammatory and pro-atherogenic role, supporting the hypothesis that these autoantibodies may play a direct causal role in CVD, and furthermore that they could potentially represent a therapeutic target for CVD in the future.
authors.affiliation: Nicolas Vuilleumier, Fabrizio Montecucco, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Vuilleumier
authors.affiliation: Nicolas Vuilleumier, Fabrizio Montecucco, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Montecucco
authors.affiliation: Nicolas Vuilleumier, Fabrizio Montecucco, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
authors.forename: Oliver
authors.initials: O
authors.lastname: Hartley
keywords: Apolipoprotein A-1; Atherosclerosis; Autoantibodies; Autoimmunity; Biomarkers; Cardiovascular disease